Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
Sponsor: Warner Chilcott
Listed as NCT00106028, this PHASE3 trial focuses on Osteogenesis Imperfecta and remains completed. Sponsored by Warner Chilcott, it has been updated 8 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Warner Chilcott
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Bristol, United Kingdom , Brussels, Belgium , Budapest, Hungary , Cologne, Germany , Dayton, United States , Glasgow, United Kingdom , Helsinki, Finland , Miami, United States , New York, United States and 10 more locations